Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05136898 · ClinicalTrials.gov registry record · Phase 3

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

A Phase 3 study of Bladder Cancer and Urothelial Carcinoma, sponsored by UroGen Pharma.

Completed
Registry status
Phase 3
Development phase
8
Enrollment target
5
Study locations

NCT05136898: Completed Phase 3 study of Bladder Cancer and Urothelial Carcinoma, sponsored by UroGen Pharma.

NCT05136898 is a Phase 3 study of Bladder Cancer and Urothelial Carcinoma that has completed, run by UroGen Pharma. The registered enrollment target is 8 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05136898, a Phase 3 study of Bladder Cancer and Urothelial Carcinoma, has completed, sponsored by UroGen Pharma.

COMPLETED
Registry status
Phase 3
Development phase
8 participants
Enrollment target
5
Study locations

Study Summary

This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Primary Outcome

The number of patients with each type of event will be summarized. TEAEs were defined as adverse events (AEs) that occurred on or after the day of the first instillation of UGN-102 or pre-treatment AEs that worsened during the study.

Conditions Studied

Bladder Cancer Urothelial Carcinoma Urothelial Carcinoma Bladder

Interventions

  • DRUG UGN-102

Study Locations (5)

Alabama

  • Urology Centers of Alabama (UCA) - Homewood

Indiana

  • Indiana University School of Medicine - Indianapolis

North Carolina

  • Medication Management - Greensboro

Tennessee

  • Urology Associates, P.C. - Nashville

Virginia

  • Virginia Urology - Richmond

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-11-30
Est. Completion 2023-02-02
Phase Phase 3
UroGen Pharma

9 total trials

What the finished NCT05136898 record still lists

NCT05136898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).

The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which UGN-102 is the first listed.

NCT05136898 lists 5 locations in 5 states (Alabama, Indiana, North Carolina).

Frequently Asked Questions

What is clinical trial NCT05136898 about?

NCT05136898 is a clinical study titled "Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)". This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG...

What is the current status of trial NCT05136898?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2021-11-30. Estimated completion is 2023-02-02.

What conditions does trial NCT05136898 study?

This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder.

What interventions are being tested in trial NCT05136898?

The interventions under investigation include: UGN-102 (DRUG).

Who is sponsoring clinical trial NCT05136898?

This trial is sponsored by UroGen Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05136898 being conducted?

This trial has 5 study locations across Alabama, Indiana, North Carolina, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05136898's enrollment target sits among peer trials

8 171st of 175 higher than 3 of 175 other Bladder Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05136898, the US trial registry maintained by the National Library of Medicine. NCT05136898 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.